EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome

Yong-Joon Lee, Xiaofei Gao iD, Sang-Hyup Lee iD, Jing Kan, Jun-Jie Zhang iD, Seung-Jun Lee, Sung-Jin Hong iD, Chul-Min Ahn, Jung-Sun Kim iD, Byeong-Keuk Kim, Young-Guk Ko iD, Donghoon Choi iD und 4 weitere

Annals of Internal Medicine · 2025

DOI: 10.7326/annals-24-03102 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Annals of Internal Medicine, 2025. Verfasst von Yong-Joon Lee und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea (Y.-J.L., S.-H.L., S.-J.L., S.-J.H., C.-M.A., J.-S.K.…. Hauptthemen laut MEDLINE: Ticagrelor, Acute Coronary Syndrome, Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The role of transitioning from short dual antiplatelet therapy (DAPT) to potent P2Y12 inhibitor monotherapy in patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation remains inconclusive. PURPOSE: To compare the effects of de-escalating DAPT to ticagrelor monotherapy versus standard DAPT from randomized clinical trials in patients with ACS. DATA SOURCES: PubMed, EMBASE, Scopus, and ClinicalTrials.gov from inception to 12 December 2024. STUDY SELECTION: Randomized clinical trials comparing de-escalating DAPT to ticagrelor monotherapy versus ticagrelor-based standard DAPT for 12 months, specifically in patients with ACS undergoing DES implantation. DATA EXTRACTION: The coprimary end points were an ischemic end point (composite of death, nonprocedural [spontaneous] myocardial infarction, or stroke) and a bleeding end point (Bleeding Academic Research Consortium types 3 or 5 bleeding). DATA SYNTHESIS: Individual patient data were obtained from 3 trials (TICO [Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus-Eluting Stent for Acute Coronary Syndrome], T-PASS [Ticagrelor Monotherapy in Patients Treated With New-Generation Drug-Eluting Stents for Acute Coronary Syndrome], and ULTIMATE-DAPT [Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes]), including 9130 randomized patients with ACS; 3132 had ST-segment elevation myocardial infarction (STEMI), 3023 had non-STEMI (NSTEMI), and 2975 had unstable angina. The rate of the primary ischemic end point was not different between the ticagrelor monotherapy and standard DAPT groups (1.7% vs. 2.1%; hazard ratio [HR], 0.85 [95% CI, 0.63 to 1.16]). The rate of the primary bleeding end point was lower in the ticagrelor monotherapy group (0.8% vs. 2.5%; HR, 0.30 [CI, 0.21 to 0.45]). These findings were consistent in patients with STEMI, NSTEMI, and unstable angina. LIMITATION: Other de-escalation strategies for modulating antiplatelet therapy were not included. CONCLUSION: In patients with ACS undergoing DES implantation, de-escalating DAPT to ticagrelor monotherapy was associated with a lower risk for major bleeding compared with standard DAPT, without an increase in ischemic events, regardless of the type of ACS. PRIMARY FUNDING SOURCE: None. (PROSPERO: CRD42024565855).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TicagrelorAcute Coronary SyndromePlatelet Aggregation InhibitorsDual Anti-Platelet TherapyPurinergic P2Y Receptor AntagonistsHumansRandomized Controlled Trials as TopicDrug-Eluting StentsHemorrhagePercutaneous Coronary InterventionDrug Therapy, Combination

Substanzen

TicagrelorPlatelet Aggregation InhibitorsPurinergic P2Y Receptor Antagonists

Autor:innen und Institutionen

  • Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea (Y.-J.L., S.-H.L., S.-J.L., S.-J.H., C.-M.A., J.-S.K., B.-K.K., Y.-G.K., D.C., M.-K.H.).
  • Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China (X.G., J.K., J.-J.Z., Y.J., S.-L.C.).
  • Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York (G.W.S.).

ORCID-Profile: Xiaofei Gao, Sang-Hyup Lee, Jun-Jie Zhang, Sung-Jin Hong, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Gregg W Stone, Shao-Liang Chen

Zitieren

APA

Lee, Y. J., Gao, X., Lee, S. H., Kan, J., Zhang, J. J., Lee, S. J., Hong, S. J., Ahn, C. M., Kim, J. S., Kim, B. K., Ko, Y. G., Choi, D., Jang, Y., Stone, G. W., Chen, S. L., & Hong, M. K. (2025). De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome. Annals of Internal Medicine. https://doi.org/10.7326/annals-24-03102

Vancouver

Lee YJ, Gao X, Lee SH, Kan J, Zhang JJ, Lee SJ, et al. De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome. Annals of Internal Medicine. 2025. doi:10.7326/annals-24-03102

BibTeX
@article{Lee2025,
  author = {Lee, Yong-Joon and Gao, Xiaofei and Lee, Sang-Hyup and Kan, Jing and Zhang, Jun-Jie and Lee, Seung-Jun and Hong, Sung-Jin and Ahn, Chul-Min and Kim, Jung-Sun and Kim, Byeong-Keuk and Ko, Young-Guk and Choi, Donghoon and Jang, Yangsoo and Stone, Gregg W and Chen, Shao-Liang and Hong, Myeong-Ki},
  title = {De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome},
  journal = {Annals of Internal Medicine},
  year = {2025},
  doi = {10.7326/annals-24-03102}
}
Kostenlos starten →